Compare JPMorgan Ultra Short Income ETF (JPST) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Mesoblast Limited — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 23.4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (240,620 versus 6,289,709). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 46 Days and Mesoblast Limited for 14 Days on average.
| JPST | MESO | |
|---|---|---|
Market Cap | $42.37B | $1.81B |
Volume | 6,289,709 | 240,620 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $20.96 |
52-Week Low | $50.22 | $13.19 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | — | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.27, up 0.04% with a bearish technical signal from moving averages. The ETF shows neutral oscillators like RSI near 35, while recent news highlights institutional selling and mixed sentiment on its yield competitiveness. Dividend payments of $0.17 are scheduled through October 2026, but key financial ratios are unavailable for fundamental assessment.
Outlook remains cautious due to technical weakness and underperformance concerns cited by analysts. Risks include interest rate sensitivity and expense ratios, but demand for ultra-short income ETFs amid market volatility offers stability. Investors should weigh yield against peer comparisons and fee structures.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
